Potential Value of HSP90 α in Prognosis of Triple-Negative Breast Cancer
CONCLUSIONS Our research findings demonstrate a significant association between high HSP90alpha expression and adverse clinical features, suggesting a poorer prognosis for TNBC patients.PMID:38553816 | DOI:10.12659/MSM.943049 (Source: Medical Science Monitor)
Source: Medical Science Monitor - March 30, 2024 Category: Research Authors: Han Fei Wang Ying Chen Bang Cao Jing Pei Source Type: research
Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes
CONCLUSION: The combination of DCE-MRI and NME-DWI via DNN achieved a significant improvement in breast cancer molecular subtype prediction compared to either imaging technique used alone. Additionally, DCE-MRI outperformed NME-DWI in differentiating subtypes.PMID:38555225 | DOI:10.1016/j.clbc.2024.03.006 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 30, 2024 Category: Cancer & Oncology Authors: Zhi-Chang Ba Hong-Xia Zhang Ao-Yu Liu Xin-Xiang Zhou Lu Liu Xin-Yi Wang Abiyasi Nanding Xi-Qiao Sang Zi-Xiang Kuai Source Type: research
Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes
CONCLUSION: The combination of DCE-MRI and NME-DWI via DNN achieved a significant improvement in breast cancer molecular subtype prediction compared to either imaging technique used alone. Additionally, DCE-MRI outperformed NME-DWI in differentiating subtypes.PMID:38555225 | DOI:10.1016/j.clbc.2024.03.006 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 30, 2024 Category: Cancer & Oncology Authors: Zhi-Chang Ba Hong-Xia Zhang Ao-Yu Liu Xin-Xiang Zhou Lu Liu Xin-Yi Wang Abiyasi Nanding Xi-Qiao Sang Zi-Xiang Kuai Source Type: research
Retracted: Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer
Biomed Res Int. 2024 Mar 20;2024:9874954. doi: 10.1155/2024/9874954. eCollection 2024.ABSTRACT[This retracts the article DOI: 10.1155/2021/6388492.].PMID:38550226 | PMC:PMC10977211 | DOI:10.1155/2024/9874954 (Source: Biomed Res)
Source: Biomed Res - March 29, 2024 Category: Research Authors: BioMed Research International Source Type: research
Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy
Bull Cancer. 2024 Mar 28:S0007-4551(24)00080-8. doi: 10.1016/j.bulcan.2024.01.011. Online ahead of print.NO ABSTRACTPMID:38553285 | DOI:10.1016/j.bulcan.2024.01.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Charl ène Rivier Pernelle Lavaud Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
Retracted: Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer
Biomed Res Int. 2024 Mar 20;2024:9874954. doi: 10.1155/2024/9874954. eCollection 2024.ABSTRACT[This retracts the article DOI: 10.1155/2021/6388492.].PMID:38550226 | PMC:PMC10977211 | DOI:10.1155/2024/9874954 (Source: Biomed Res)
Source: Biomed Res - March 29, 2024 Category: Research Authors: BioMed Research International Source Type: research
Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy
Bull Cancer. 2024 Mar 28:S0007-4551(24)00080-8. doi: 10.1016/j.bulcan.2024.01.011. Online ahead of print.NO ABSTRACTPMID:38553285 | DOI:10.1016/j.bulcan.2024.01.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Charl ène Rivier Pernelle Lavaud Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy
Bull Cancer. 2024 Mar 28:S0007-4551(24)00080-8. doi: 10.1016/j.bulcan.2024.01.011. Online ahead of print.NO ABSTRACTPMID:38553285 | DOI:10.1016/j.bulcan.2024.01.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Charl ène Rivier Pernelle Lavaud Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
Trastuzumab-deruxtecan monotherapy in HER2-activated advanced non-small cell lung cancer pre-treated with platinum-based chemotherapy with or without immunotherapy
Bull Cancer. 2024 Mar 28:S0007-4551(24)00080-8. doi: 10.1016/j.bulcan.2024.01.011. Online ahead of print.NO ABSTRACTPMID:38553285 | DOI:10.1016/j.bulcan.2024.01.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Charl ène Rivier Pernelle Lavaud Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
Literature review Analysis of the Current State of Targeted Therapy for Gastrointestinal Cancers
This article provided a clinical summary of the most recent advances in targeted treatment for GEC and the supporting clinical data, such as their efficacy and safety profiles.PMID:38551425 (Source: Alternative Therapies in Health and Medicine)
Source: Alternative Therapies in Health and Medicine - March 29, 2024 Category: Complementary Medicine Authors: Xinge Miao Chenxing Jin Xiang Ji Yibin Teng Jiwei Liu Source Type: research
Cancers, Vol. 16, Pages 1336: HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments
enzen
Despite a decreasing incidence in Western countries, gastric cancer is among the most common cancer subtypes globally and is associated with one of the highest tumor-related mortality rates. Biomarkers play an increasing role in the treatment against gastric cancer. HER2 was one of the first biomarkers that found its way into clinical practice. Since the ToGA trial, trastuzumab has been part of first-line palliative chemotherapy in metastatic or unresectable gastric cancer. HER2-targeting agents, such as the tyrosine kinase inhibitor lapatinib, the antibody drug conjugate (ADC) trastuzumab-emtansine or dual HER2 ...
Source: Cancers - March 29, 2024 Category: Cancer & Oncology Authors: Magdalena K. Scheck Ralf D. Hofheinz Sylvie Lorenzen Tags: Review Source Type: research
